Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:44c2:0:b0:439:fcfb:30e with SMTP id z2csp3112220wrr; Tue, 17 Mar 2026 10:36:09 -0700 (PDT) X-Received: by 2002:a05:620a:7083:b0:8cd:94a5:2f1f with SMTP id af79cd13be357-8cfad38a6c7mr52054485a.60.1773768968728; Tue, 17 Mar 2026 10:36:08 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1773768968; cv=none; d=google.com; s=arc-20240605; b=ffU5mWkQUUVCqWoJjNFJnOMwduKGa25h+Jf/WwYZT0zdhfoSeLPNAThmEtfNtsCz9z zohReRTabnjJAYhs5PKTUIqdBa1yJlqa+HspaouE5jhR/OcknQfNXSojyhylXKw9Vsrb kMg/eNxbVRQLaACwctves0pma1/yaGFlttH1ljFWk1OXqdVvXCoUcLgMP137Ejg/qIQ8 fSEEN14q4XD9yUhLdHXTh15h/efuWO2a1p6SZdoU9fiLwYsiuBsocMxERv2DfoCILenZ VSdXT2xvoX/nTWo/FTubsRHhw8GHI+O2C1Oq5c0D4GKb0EDl5Z3KwKIJOwnH1lFc/rCt 6lEw== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:list-unsubscribe:list-unsubscribe-post:to:from:subject :mime-version:date:dkim-signature:dkim-signature; bh=KHfJVgVd5BWm3X8muTiCt/pR+lq9fs6TJXbl2YFPMrY=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=IZWfQVJYIxnc+UNhP2Fa/kytXVLMTavslsm/l0X/nEHzYdWjbp5J+CuOcnrTPV0sDF Od2MJNeXjIXyS6t0RVquZ3itUX2PZXFg1/1A6h3VKIW+XqmFQE3E0JCRYe53U9nPH66a 9xZ9tnUVzo8bAem/ITOLOyUp/PdKTIgdwEK7G3b+REfVzChFxR6/CpoQpJbAsxtZl3Ph nqIPnsn4CDV8lKQHHeeLRrxnA/Zd2D+S1mh+JFGXgGFbLLBcXpvWdTrCfs+63R9D0mPG 85xxmkD9Y8ZtmpOAjT5IgGuDMrl+IQi4tUNHtzb5lOO1jWvQcQ1y2EuD2/I/1XaWwZhb Ng6w==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@cio113215.seedoilscout.com header.s=mx header.b=WZtMcHht; dkim=pass header.i=@mailgun.org header.s=mg header.b=szeyZQbh; spf=pass (google.com: domain of postmaster@cio113215.seedoilscout.com designates 161.38.193.63 as permitted sender) smtp.mailfrom=postmaster@cio113215.seedoilscout.com; dmarc=pass (p=REJECT sp=QUARANTINE dis=NONE) header.from=seedoilscout.com Return-Path: Received: from v563.v56f0a4e3.use4.send.mailgun.net (v563.v56f0a4e3.use4.send.mailgun.net. [161.38.193.63]) by mx.google.com with UTF8SMTPS id af79cd13be357-8cfad248123si40089085a.242.2026.03.17.10.36.08 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Tue, 17 Mar 2026 10:36:08 -0700 (PDT) Received-SPF: pass (google.com: domain of postmaster@cio113215.seedoilscout.com designates 161.38.193.63 as permitted sender) client-ip=161.38.193.63; Authentication-Results: mx.google.com; dkim=pass header.i=@cio113215.seedoilscout.com header.s=mx header.b=WZtMcHht; dkim=pass header.i=@mailgun.org header.s=mg header.b=szeyZQbh; spf=pass (google.com: domain of postmaster@cio113215.seedoilscout.com designates 161.38.193.63 as permitted sender) smtp.mailfrom=postmaster@cio113215.seedoilscout.com; dmarc=pass (p=REJECT sp=QUARANTINE dis=NONE) header.from=seedoilscout.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=cio113215.seedoilscout.com; q=dns/txt; s=mx; t=1773768968; x=1773776168; h=Message-Id: List-Unsubscribe: List-Unsubscribe-Post: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: X-Feedback-Id: Sender; bh=KHfJVgVd5BWm3X8muTiCt/pR+lq9fs6TJXbl2YFPMrY=; b=WZtMcHhtZGTbhvE8oBYqPo8hf1k591Opq9t0CCSm8Tyjk1umrBMH5+4FThwrukfvehPxtx8zybN4+EnVxnH1iaiOpkxgkpWjJxsJBg/j0Sr4vPvGZN6eSojdQgGyP1pVHgANzrKqqpN2+iQiHdlj8UnkLQz0vzqLFDtilmtmLoA= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1773768968; x=1773776168; h=Message-Id: List-Unsubscribe: List-Unsubscribe-Post: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: X-Feedback-Id: Sender; bh=KHfJVgVd5BWm3X8muTiCt/pR+lq9fs6TJXbl2YFPMrY=; b=szeyZQbhuoyOc7xzz4BI4D+qtSleGmWOHctTX6OvTrO/lOxlQWHlKzgyFRMZ2SaacJr4lJax/n3gWZ4J6DuHX5b1TAwetKbjZlGhpLmgJQa5YY7gHBZKduhQskKAyRYEolvTQ8mP6vOktxUBLvz0qkPxNUmDdx7X6i/BwnOaLjk= X-Mailgun-Sid: WyIzNzBhZSIsInRqcGh1aHNAZ21haWwuY29tIiwiODk3ZmY0Il0= X-Feedback-Id: postmaster@cio113215.seedoilscout.com::6745de0208fa6bd02093433f:mailgun Received: by b0df4a4ac9debac610720d7737fa4ce7f53c1d23ed022407e0947e0740cae3c5 with HTTP id 69b99107a85ec441424fd780; Tue, 17 Mar 2026 17:36:07 GMT X-Mailgun-Sending-Ip: 161.38.193.63 Date: Tue, 17 Mar 2026 17:36:07 +0000 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="b1d9d4cff25a286e0d3bf4663f49c49ce6969341e6ad651b3dce94de230c" Subject: When Ozempic stops working (and what 10% of users already know) From: Seed Oil Scout To: tjphuhs@gmail.com X-Mailgun-Dkim: true X-Mailgun-Native-Send: true X-Mailgun-Track-Clicks: false X-Mailgun-Track-Opens: false List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailer: Customer.io (dgSUsgoDAI2jMYyjMQGc_NERjvQvmzgM7bvbNmA=; +https://whatis.customeriomail.com) X-Report-Abuse-To: badactor@customer.io List-Unsubscribe: , X-Mailgun-Variables: {"email_id": "dgSUsgoDAI2jMYyjMQGc_NERjvQvmzgM7bvbNmA="} Message-Id: <20260317173607.cafbfd0e68db45c7@cio113215.seedoilscout.com> --b1d9d4cff25a286e0d3bf4663f49c49ce6969341e6ad651b3dce94de230c Content-Transfer-Encoding: quoted-printable Content-Type: text/plain; charset="utf-8" The non-responder problem, the plateau trap, and the side effects pharma bu= ries in the fine print. =C2=A0 ****************************************************************** When Ozempic Stops Working: The 1-in-10 Problem Nobody Talks About ****************************************************************** ( https://eatprima.com/discount/SOS15 ) PRIMA ( https://eatprima.com/discount/SOS15 ) just leveled up. Now packed w= ith 21g of grass-fed protein, it=E2=80=99s the same ancestral bar you trust= =E2=80=94 only better. Better texture. Better taste. More of what actually fuels you. Use SOS15 for 15% off on your first purchase ( https://eatprima.com/discoun= t/SOS15 ) GLP-1 drugs have been called miracle treatments. But roughly 10% of users a= re "non-responders," and a growing number of long-term users are hitting pl= ateaus. What happens when the magic wears off? =E2=80=8A ************************* The Non-Responder Problem ************************* In the=C2=A0STEP 1 trial ( https://pubmed.ncbi.nlm.nih.gov/33567185/ ), abo= ut 1 in 10 semaglutide users failed to lose even 5% of body weight, the min= imum threshold considered clinically meaningful. In the=C2=A0SURMOUNT-2 tri= al ( https://pubmed.ncbi.nlm.nih.gov/37385275/ )=C2=A0for tirzepatide, 17-2= 1% of participants didn't hit that 5% mark. =C2=A0 Why? Variants in the GLP-1 receptor gene affect how strongly the drug signa= ls satiety.=C2=A0Gut microbiome composition ( https://pubmed.ncbi.nlm.nih.g= ov/41079186/ )=C2=A0also influences response. And if your metabolism is alr= eady adapted to caloric restriction from years of yo-yo dieting, these drug= s have less runway to work with. =E2=80=8A ************** Plateau Nation ************** Even among responders, the ride doesn't last forever. The=C2=A0STEP 1 exten= sion study ( https://pubmed.ncbi.nlm.nih.gov/35441470/ )=C2=A0found that af= ter stopping semaglutide, participants regained two-thirds of their lost we= ight within one year. Cardiometabolic improvements reverted toward baseline= too. =C2=A0 But it's not just about stopping. Users 12+ months in report stalls even wh= ile still on the drug. The response: dose escalation. Higher dose, more sid= e effects, diminishing returns. Weight loss curves flatten between months 1= 2 and 18. Your body adapts, the same way it adapts to every other weight-lo= ss intervention ever tried. =E2=80=8A ******************************************* The Side Effects Nobody Wants to Talk About ******************************************* GLP-1 drugs aren't just nausea and constipation. The side effect profile ge= ts darker the longer you look: * Muscle loss: Up to=C2=A040% of weight lost on semaglutide is lean mass ( ht= tps://pubmed.ncbi.nlm.nih.gov/34706925/ ), not fat. That's muscle, bone den= sity, and metabolic tissue you need to age well. * Gastroparesis: The FDA added a=C2=A0warning about delayed gastric emptying = ( https://www.fda.gov/safety/medical-product-safety-information/ozempic-sem= aglutide-marketed-type-2-diabetes-mellitus )=C2=A0so severe it can cause bo= wel obstruction. Some users report symptoms persisting after stopping the d= rug. * Gallbladder disease:=C2=A0Clinical trials ( https://www.accessdata.fda.gov/= drugsatfda_docs/label/2023/215256s007lbl.pdf )=C2=A0documented cholelithias= is (gallstones) at rates 2-3x higher than placebo. Rapid weight loss plus a= ltered bile metabolism is a known recipe. * Pancreatitis: The=C2=A0FDA label for semaglutide ( https://www.accessdata.f= da.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf )=C2=A0carries a warnin= g for acute pancreatitis. Rates are low but the condition is serious. * Thyroid tumors: All GLP-1 drugs carry a=C2=A0boxed warning ( https://www.ac= cessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf )=C2=A0about = thyroid C-cell tumors based on animal studies. Contraindicated in patients = with a personal or family history of medullary thyroid carcinoma. * "Ozempic face": The gaunt, aged facial appearance from rapid fat and muscle= loss. It's cosmetic, but it signals something deeper: your body is canniba= lizing tissue, not just fat. =E2=80=8A ************************************** Retatrutide and the Heart Rate Problem ************************************** Retatrutide is Eli Lilly's triple agonist (GIP/GLP-1/glucagon). Early resul= ts:=C2=A0up to 24.2% weight loss at 48 weeks ( https://pubmed.ncbi.nlm.nih.= gov/37366315/ )=C2=A0per the=C2=A0NEJM=C2=A0Phase 2 trial. But buried in th= e data: dose-dependent increases in heart rate peaking at 24 weeks. =C2=A0 The glucagon receptor component is the likely culprit. At the 12mg dose, he= art rate elevations were clinically notable. Users report resting heart rat= es climbing 10-20 bpm. For a drug class prescribed to people already at ele= vated cardiovascular risk, that should raise questions, not just heart rate= s. =E2=80=8A **************************** What Non-Responders Discover **************************** Here's the irony. When GLP-1 drugs stop working (or never start), patients = are forced back to the basics that actually build metabolic health: * Protein: 1g per pound of ideal body weight. Protects lean mass, drives sa= tiety without a prescription. * Sleep: Poor sleep=C2=A0increases ghrelin and tanks leptin sensitivity ( htt= ps://pubmed.ncbi.nlm.nih.gov/15602591/ ). No drug fixes that. * Real fats: Butter, tallow, olive oil. The kind that signal fullness and don= 't require a weekly injection. (And yes, avoiding seed oils.) The metabolic foundation that drugs can't replace is the same one it's alwa= ys been: eat real food, move, sleep. =E2=80=8A *********** Bottom Line *********** * About 10% of GLP-1 users are non-responders, and many more hit plateaus a= fter 12 months. * After stopping semaglutide, people regain two-thirds of lost weight within = a year. * Side effects include significant muscle loss, gallbladder disease, gastro= paresis, pancreatitis risk, and thyroid concerns. * Retatrutide shows dose-dependent heart rate increases that deserve more s= crutiny. * When the drug stops working, the answer is the same as it always was: prote= in, sleep, real food. GLP-1 drugs work for most people. But they're not a permanent fix for a bro= ken food system.=C2=A0 =E2=80=8A ( https://eatprima.com/discount/SOS15 ) PRIMA JUST GOT STRONGER. ( https://eatprima.com/discount/SOS15 ) 21 grams of grass-fed protein. Same real whole-food ingredients. Better tex= ture. Better taste. The ancestral protein bar you already trusted =E2=80=94= now with more of what you asked for. No seed oils, ever. No isolates. No s= yrups. No shortcuts. Just real food, done right. [ SHOP THE NEW FORMULA ] ( https://eatprima.com/discount/SOS15 ) =E2=80=8A Did you like this newsletter? Loved it! ( https://forms.seedoilscout.com/r/nW7l0L?platform=3Dcustomerio )= =E2=9D=A4=EF=B8=8F It could be better. ( https://forms.seedoilscout.com/r/wdyQPN?platform=3Dcu= stomerio ) =F0=9F=91=8E Seed Oil Scout subscriptions keep this newsletter afloat! Get unlimited acc= ess to clean dining globally for a deep discount of $19.99 when you join he= re ( https://buy.stripe.com/7sI7sHeWq1Rna9qdQY?client_reference_id=3Dplatfo= rm_customerio ) ( https://open.seedoilscout.com/ ) ( https://www.instagram.com/seedoilscout/?hl=3Den ) ( https://www.facebook.com/seedoilscout/ ) ( https://x.com/SeedOilScout ) ( https://www.youtube.com/@SeedOilScout ) ( https://open.seedoilscout.com/ ) ( https://www.instagram.com/seedoilscout/?hl=3Den ) ( https://www.facebook.com/seedoilscout/ ) ( https://x.com/SeedOilScout ) ( https://www.youtube.com/@SeedOilScout ) =C2=A9 2025 Seed Oil Scout=E2=80=99s Newsletter 108 W 13th Street Wilmington, DE 19801, United States of America unsubscribe ( https://track.customer.io/unsubscribe/dgSUsgoDAI2jMYyjMQGc_NE= RjvQvmzgM7bvbNmA=3D ) --b1d9d4cff25a286e0d3bf4663f49c49ce6969341e6ad651b3dce94de230c Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="utf-8" 96
The non-responder problem, the plateau trap, and the side effects phar= ma buries in the fine print. =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD= =8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80= =87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F = =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87= =CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2= =80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD= =8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80= =87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F = =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87= =CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2= =80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD= =8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80= =87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F = =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87= =CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2= =80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD= =8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80= =87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F = =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87= =CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2= =80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD= =8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =E2=80= =87=CD=8F =E2=80=87=CD=8F =E2=80=87=CD=8F =C2=AD =C2=AD =C2=AD =C2=AD =C2= =AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD = =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2= =AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD = =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2= =AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD = =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2= =AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD = =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2= =AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD =C2=AD = =C2=AD =C2=AD =C2=AD=C2=A0
<= /tr>
3D""
3D""
<= /div>
<= /tr>

When Ozempic Stops Working: = The 1-in-10 Problem Nobody Talks About

<= tbody>
3D""=

PRIMA just leveled = up. Now packed with 21g of grass-fed protein, it=E2=80=99s= the same ancestral bar you trust =E2=80=94 only better.
Better texture= =2E Better taste. More of what actually= fuels you.

Use SOS15 for 15% off on your fi= rst purchase

=

GLP-1 drugs have been called miracle treatments. But roughly 10% of users a= re "non-responders," and a growing number of long-term users are hi= tting plateaus. What happens when the magic wears off?

<= div class=3D"alignment" align=3D"center">
=E2=80=8A

The Non-Responder Problem

<= table class=3D"text_block block-4" width=3D"100%" border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" style=3D"mso-table-lspace:0;= mso-table-rspace:0;word-break:break-word">

In the=C2=A0STEP 1 trial, about 1 in 10 semaglutide users= failed to lose even 5% of body weight, the minimum threshold considered cl= inically meaningful. In the=C2=A0SURMOUNT-= 2 trial=C2=A0for tirzepatide, 17-21% of participants didn't hit that 5%= mark.

=C2=A0

Why? Variants in t= he GLP-1 receptor gene affect how strongly the drug signals satiety.=C2=A0<= a href=3D"https://e.customeriomail.com/e/c/eyJlbWFpbF9pZCI6ImRnU1VzZ29EQUky= ak1ZeWpNUUdjX05FUmp2UXZtemdNN2J2Yk5tQT0iLCJocmVmIjoiaHR0cHM6Ly9wdWJtZWQubmN= iaS5ubG0ubmloLmdvdi80MTA3OTE4Ni8iLCJpbnRlcm5hbCI6Ijk0YjIwYTFhYWNkNTAxOGRhMz= MxIiwibGlua19pZCI6ODg5OX0/15b2af1cdfe8d083e62b8c3f2164659a251445731c7bcc84f= 5b98038ae4b449c" target=3D"_blank" style=3D"text-decoration: underline; col= or: #065a4b;" rel=3D"noopener">Gut microbiome composition=C2=A0also inf= luences response. And if your metabolism is already adapted to caloric rest= riction from years of yo-yo dieting, these drugs have less runway to work w= ith.

<= /tbody>
<= /table>
=E2=80=8A

Plateau Nation

Even among respond= ers, the ride doesn't last forever. The=C2=A0STEP 1 extension study=C2=A0found that after stopping semaglutide, pa= rticipants regained two-thirds of their lost weight within one year. Cardio= metabolic improvements reverted toward baseline too.

=C2=A0

But it's not just = about stopping. Users 12+ months in report stalls even while still on the d= rug. The response: dose escalation. Higher dose, more side effects, diminis= hing returns. Weight loss curves flatten between months 12 and 18. Your bod= y adapts, the same way it adapts to every other weight-loss intervention ev= er tried.

=E2=80=8A

The Side Effects Nobody Wants to Talk About

<= table class=3D"text_block block-10" width=3D"100%" border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" style=3D"mso-table-lspace:0;= mso-table-rspace:0;word-break:break-word">

GLP-1 drugs aren't just nausea and constipatio= n. The side effect profile gets darker the longer you look:

  • Muscle los= s: Up to=C2=A040% of weight lost o= n semaglutide is lean mass, not fat. That's muscle, bone density, and m= etabolic tissue you need to age well.
  • Gastropare= sis: The FDA added a=C2=A0warning about delayed gastric emptying=C2=A0so severe i= t can cause bowel obstruction. Some users report symptoms persisting after = stopping the drug.
  • Gallbladde= r disease:=C2=A0Clinical trials=C2=A0documented cholelithias= is (gallstones) at rates 2-3x higher than placebo. Rapid weight loss plus a= ltered bile metabolism is a known recipe.
  • Pancreatit= is: The=C2=A0FDA label for semaglutide=C2=A0carries a warnin= g for acute pancreatitis. Rates are low but the condition is serious.
  • Thyroid tu= mors: All GLP-1 drugs carry a=C2=A0boxed warning=C2=A0about = thyroid C-cell tumors based on animal studies. Contraindicated in patients = with a personal or family history of medullary thyroid carcinoma.
  • "Ozemp= ic face": The gaunt, aged facial appearance from rapid fat and= muscle loss. It's cosmetic, but it signals something deeper: your body is = cannibalizing tissue, not just fat.
=
=E2=80=8A

Ret= atrutide and the Heart Rate Problem

Retatrutide is Eli= Lilly's triple agonist (GIP/GLP-1/glucagon). Early results:=C2=A0up to 24.2% weight loss at 48 weeks=C2=A0per t= he=C2=A0NEJM=C2=A0Phase 2 trial. But buried in the data: dose-depe= ndent increases in heart rate peaking at 24 weeks.

=C2=A0

The glucagon receptor component is the likely cu= lprit. At the 12mg dose, heart rate elevations were clinically notable. Use= rs report resting heart rates climbing 10-20 bpm. For a drug class prescrib= ed to people already at elevated cardiovascular risk, that should raise que= stions, not just heart rates.

<= td class=3D"pad">
<= /table>
=E2=80=8A
<= td class=3D"pad" style=3D"padding-top:5px;text-align:center;width:100%">What Non-Responders Discover
<= table class=3D"text_block block-16" width=3D"100%" border=3D"0" cellpadding= =3D"0" cellspacing=3D"0" role=3D"presentation" style=3D"mso-table-lspace:0;= mso-table-rspace:0;word-break:break-word">

Here's the irony. When GLP-1 drugs stop workin= g (or never start), patients are forced back to the basics that actually bu= ild metabolic health:

  • Protein: 1g per pound of ideal body weight. Protects lean ma= ss, drives satiety without a prescription.
  • Sleep: Poor sleep=C2=A0increases ghrelin and= tanks leptin sensitivity. No drug fixes that.
  • Real fats<= /strong>: Butter, tallow, olive oil. The kind that signal fullness and don'= t require a weekly injection. (And yes, avoiding seed oils.)

    • The metabolic foundation that= drugs can't replace is the same one it's always been: eat real food, move,= sleep.

=
=E2=80=8A

Bottom Line

  • About 10% of GLP-1 users are non-responders, and many mo= re hit plateaus after 12 months.
  • After stopping sem= aglutide, people regain two-thirds of lost weight within a year.
  • Side effects = include significant muscle loss, gallbladder disease, gastroparesis, pancre= atitis risk, and thyroid concerns.
  • Retatrutide shows dose-dependent heart rate= increases that deserve more scrutiny.
  • When the drug stop= s working, the answer is the same as it always was: protein, sleep, real fo= od.

GLP-1 drugs= work for most people. But they're not a permanent fix for a broken food sy= stem.=C2=A0

=E2=80= =8A

PRIMA JUST= GOT STRONGER.
21 grams of grass-= fed protein. Same real whole-food ingredients. Better texture. Better taste= =2E The ancestral protein bar you al= ready trusted =E2=80=94 now with more of=20= what you asked for. No seed oils, ever. No isolates. No syrups. No shortcuts. Just rea= l food, done right.

[ SHOP THE NEW FORMULA ]

<= /td>
=E2=80=8A
<= /div>

Did you like this newslett= er?
Loved it! =E2=9D=A4=EF= =B8=8F
= It could be better. =F0=9F=91=8E<= /span>

Seed Oil Scout sub= scriptions keep this newsletter afloat! Get unlimited access to clean dinin= g globally for a deep discount of $19.99 when you join here

3D""
3D""
3D""
3D""
= =
3D""
=
3D""
3D""<= /div>

=C2=A9 2025 Seed Oil Scout= =E2=80=99s Newsletter
108 W 13th Street

Wilmington, DE 19801,
United States of America

=

3D""/ --b1d9d4cff25a286e0d3bf4663f49c49ce6969341e6ad651b3dce94de230c--